Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Venetoclax Combined With Intermediate-dose Cytarabine Versus Intermediate-dose Cytarabine for Consolidation Therapy of Acute Myeloid Leukemia (AML): a Multicenter, Prospective, Randomized Controlled, Phase 2 Study

NCT07537257 is registered in ClinicalTrials.gov with Guangdong Second Provincial General Hospital as lead sponsor.

NCT NCT07537257
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07537257 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Venetoclax Combined With Intermediate-dose Cytarabine Versus Intermediate-dose Cytarabine for Consolidation Therapy of Acute Myeloid Leukemia (AML): a Multicenter, Prospective, Randomized Controlled, Phase 2 Study
Lead sponsor
Guangdong Second Provincial General Hospital
Phase
Phase 2/3
Overall status
Enrolling by invitation
Start date
April 1, 2026
Completion date
April 1, 2029
Enrollment
232 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aml (acute myelogenous leukemia)